Live Short Cuts
事前に注目していた演題を、聴講直後のホットな状態のまま
現地サンフランシスコでコメント収録。
更新履歴
演題レポート
Oral
Abstract #1
Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ?T3 resectable gastric cancer: CCOG1102
Daishi Morimoto, et al.
Abstract #4
Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial
Florian Lordick, et al.
Abstract #5
RAINFALL: A randomized, double-blind, placebo-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma
Charles S. Fuchs, et al.
Abstract #205
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113)
Chigusa Morizane, et al.
Abstract #206
Randomized, open label, multicenter, phase II trial of Transcatheter Arterial Chemoembolization (TACE) Therapy In Combination with Sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo, et al.
Abstract #207
Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
Ghassan K. Abou-Alfa, et al.
Abstract #557
REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.
Kohei Shitara, et al.
Poster
Abstract #734
A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial)
Hiroyuki Uetake, et al.
Abstract #745
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer with prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G
Hiroya Taniguchi, et al.
監修・レポーター
監修
谷口 浩也先生
愛知県がんセンター中央病院 薬物療法部 医長
レポーター
賀川 義規先生
関西ろうさい病院 下部消化器外科 副部長
#745
監修
山﨑 健太郎先生
静岡県立静岡がんセンター 消化器内科 医長
レポーター
山本 祥之先生
筑波大学附属病院 消化器内科 病院講師
#557
監修
上野 誠先生
神奈川県立がんセンター 消化器内科 医長
レポーター
高橋 秀明先生
国立がん研究センター東病院 肝胆膵内科 医員
#207